<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00858793</url>
  </required_header>
  <id_info>
    <org_study_id>ARL-GT 2005</org_study_id>
    <nct_id>NCT00858793</nct_id>
  </id_info>
  <brief_title>High-dose Chemotherapy With Transplantation of Gene-modified Haematopoietic Stem Cells for HIV-positive Patients With Malignant Diseases Indicating an HSCT</brief_title>
  <official_title>High-dose Chemotherapy With Transplantation of Gene-modified Haematopoietic Stem Cells for HIV-positive Patients With Malignant Diseases Indicating an HSCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patient stem cells will be mobilized with induction chemotherapy (R)-ICE and G-CSF. If&#xD;
      sufficient cells can be mobilized, patients will be treated with high-dose chemotherapy and a&#xD;
      transplant of autologous CD34+ cells transduced with an antiviral vector (M87o). If&#xD;
      autologous CD34+ yield is insufficient, allogeneic gene-modified cells will be given, if a&#xD;
      compatible donor is available. To minimize risk of transplant failure, a second unmodified&#xD;
      CD34+ cell transplant will be given one week after the first transplant.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 28, 2008</start_date>
  <completion_date type="Actual">August 31, 2016</completion_date>
  <primary_completion_date type="Actual">August 31, 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events, ECOG performance status and laboratory safety tests</measure>
    <time_frame>five years after transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Remission status (CR or PR)</measure>
    <time_frame>five years after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any relapse of ARL</measure>
    <time_frame>five years after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>level and kinetics of engraftment and level of gene marking</measure>
    <time_frame>five years after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral load</measure>
    <time_frame>five years after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 counts</measure>
    <time_frame>five years after transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>AIDS-related Lymphoma</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PBSC-M87o, Gene (M87o)-modified, CD34+ peripheral blood progenitor cells (PBSC)</intervention_name>
    <description>Patient stem cells will be mobilized with induction chemotherapy (R)-ICE and G-CSF. If sufficient cells can be mobilized, patients will be treated with high-dose chemotherapy and a transplant of autologous CD34+ cells transduced with an antiviral vector (M87o). If autologous CD34+ yield is insufficient, allogeneic gene-modified cells will be given, if a compatible donor is available. To minimize risk of transplant failure, a second unmodified CD34+ cell transplant will be given one week after the first transplant.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female patients of any ethnic group aged between 18 and 65 years&#xD;
&#xD;
          -  HIV-positive patients with malignant diseases of the blood (NHL, Hodgkin disease,&#xD;
             plasmocytoma, acute and chronic leukaemia) who failed to achieve complete remission&#xD;
             (CR) after standard-dose first-line chemotherapy or had a chemosensitive relapse after&#xD;
             an initial CR&#xD;
&#xD;
          -  Patients must receive HAART&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any of the following conditions:&#xD;
&#xD;
               -  congestive heart failure (NYHA &gt; II)&#xD;
&#xD;
               -  documented EBV, HBV or HCV infection (only for allogeneic PBSCT)&#xD;
&#xD;
               -  creatinine clearance &lt; 60 ml/min&#xD;
&#xD;
               -  left ventricular ejection fraction &lt; 40%&#xD;
&#xD;
               -  bilirubin &gt; 2 mg/dl&#xD;
&#xD;
          -  Severe opportunistic infection&#xD;
&#xD;
          -  More than 10% of bone marrow involved with lymphoma&#xD;
&#xD;
          -  Between 2 and 5 10^6 autologous CD34+ cells/kg BW obtained after leukapheresis and&#xD;
             CD34 enrichment&#xD;
&#xD;
          -  Women of child.bearing potential not under adequate contraceptive protection&#xD;
&#xD;
          -  Women who are pregnant or breast feeding&#xD;
&#xD;
          -  Known history of drug-, medication- or alcohol abuse within the last 12 months&#xD;
             preceding the study&#xD;
&#xD;
          -  Participation in another study with an investigational product within less than one&#xD;
             month prior to this study&#xD;
&#xD;
          -  Simultaneous participation in a study with an investigational drug&#xD;
&#xD;
          -  Presence of any disease likely to require procedures altering the schedule of the&#xD;
             protocol&#xD;
&#xD;
          -  Patients with a history of seizures, central nervous system disorders or psychiatric&#xD;
             disability thought to be clinically significant in the opinion of the investigator&#xD;
&#xD;
          -  Patients with limited mental capacity to the extent that he/she cannot provide&#xD;
             informed consent or information regarding adverse events of the study medication&#xD;
&#xD;
          -  Patients with any clinically meaningful renal, hepatic, respiratory or cardiovascular&#xD;
             disease&#xD;
&#xD;
          -  Patients who have previously been admitted to this study&#xD;
&#xD;
          -  Patients who will not accept transfusions of blood products&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolaus Kroeger</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Hamburg-Eppendorf, Department for Stem Cell Transplantation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>March 9, 2009</study_first_submitted>
  <study_first_submitted_qc>March 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2009</study_first_posted>
  <last_update_submitted>May 26, 2017</last_update_submitted>
  <last_update_submitted_qc>May 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AIDS</keyword>
  <keyword>HIV</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Stem Cell Transplantation</keyword>
  <keyword>gene-modified Stem Cells</keyword>
  <keyword>treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, AIDS-Related</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

